Miami-based eMed has raised more than $200 million in a Series A funding round, valuing the company at over $2 billion. The healthcare platform, which focuses on employer-based population health solutions, is advancing an AI-driven model designed to improve treatment outcomes and manage healthcare costs. According to the company, the round was led by AON Consulting, with participation from a group of high-profile investors including Tom Brady, eMed Founding Chief Wellness Officer, Jeff Aronin, Founder, Chairman, and CEO of Paragon Biosciences, Antonio Gracias, Founder and CEO of Valor Equity Partners, and eMed CEO, Linda Yaccarino.
Brady, who also serves as the company’s Founding Chief Wellness Officer, said, “I believe eMed's empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula.” The funding will support further development of its AI platform and strengthen its financial position.
eMed is focusing on expanding access to clinically managed GLP-1 programs, which are increasingly in demand as workplace health benefits. The company aims to address a gap where only a small portion of employers currently offer such treatments despite strong demand. Its program emphasizes sustained patient engagement, reporting adherence rates above 90%, significantly higher than industry averages.
According to the company, this approach has resulted in measurable outcomes, including average weight loss and improvements in key health indicators within months. With the new capital, eMed plans to scale its services and introduce a new payment model designed to help employers better manage rising healthcare expenses while improving employee health outcomes.
